New cancer drug enters human testing for Tough-to-Treat tumors
NCT ID NCT07124117
Summary
This early-stage study is testing a new drug called OBI-902 in people with advanced solid tumors that have not responded to standard treatments. Researchers aim to find the safest and most effective dose and see if the drug shows early signs of shrinking tumors. The study will enroll about 147 adults with specific cancers like bile duct, stomach, and ovarian cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
China Medical University Hospital
RECRUITINGTaichung, 404327, Taiwan
Contact
-
NEXT Oncology
RECRUITINGSan Antonio, Texas, 78229, United States
Contact
-
Scripps Green Hospital
RECRUITINGLa Jolla, California, 92037, United States
Contact
-
Shuang Ho Hospital
ACTIVE_NOT_RECRUITINGTaipei, Zhonghe, 23561, Taiwan
-
The University of Texas MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact
-
Wan Fan Hospital
RECRUITINGTaipei, Wenshan, 116, Taiwan
Contact
Conditions
Explore the condition pages connected to this study.